Henrik Loft Jakobsen

Henrik Loft Jakobsen

Auto-generated profile, based on publicly available information

Henrik Loft Jakobsen

Department of Surgery, Herlev Hospital, Copenhagen University Hospital, 2730 Herlev, Denmark

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2021 in Annals of Surgery
Verified
Journal Article
Closed access
NDNiclas Dohrn
Niclas Dohrn
HYHelin Yikilmaz
Helin Yikilmaz
MLMagnus Laursen
Magnus Laursen
FKFaisal Khesrawi
Faisal Khesrawi
FCFrederik Bjerg Clausen
Frederik Bjerg Clausen
Ismail GögenurIsmail Gögenur
Ismail Gögenur
Objective: To determine if minimally invasive right colectomy with intra-corporeal anastomosis improves postoperative recovery compared to extra-corporeal anastomosis. Background: Previous trials have shown that intracorporeal anastomosis improves postoperative recovery; however, it has not yet been evaluated in a setting with optimized perioperative care or with patient-related outcome measures. Methods: This was a multicenter, triple-blind, randomized clinical trial at two high-volume colorectal centers with strict adherence to optimized perioperative care pathways. The patients underwent robotic right colectomy with either intracorporeal or extracorporeal anastomosis. The primary outcome was patient-reported postoperative recovery measured using the “Quality of Recovery–15” questionnaire. ClinicalTrials.gov NCT03130166. Results: A total of 89 patients were randomized and analyzed according to the “Intention-to-treat”-principle. We found no statistically significant differences in patient-reported recovery between the groups. Postoperative pain, nausea, time to ambulation, time to first passage of flatus/stool, length of hospital stay, and pathophysiological tests showed no differences either. The duration of time to create the anastomosis was significantly longer with intracorporeal anastomosis (17 vs 13 min, P = 0.003), while all other intraoperative, postoperative, and pathology variables showed no difference. Conclusion: There were no significant differences in postoperative recovery between the two groups.

18 March 2015 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
MVM Vester-Andersen
M Vester-Andersen
TWT Waldau
T Waldau
JWJ Wetterslev
J Wetterslev
MMM H Møller
M H Møller
JRJacob Rosenberg
Jacob Rosenberg
LBL Bugge
L Bugge
Background: Emergency abdominal surgery carries a considerable risk of death and postoperative complications. Early detection and timely management of complications may reduce mortality. The aim was to evaluate the effect and feasibility of intermediate care compared with standard ward care in patients who had emergency abdominal surgery. Methods: This was a randomized clinical trial carried out in seven Danish hospitals. Eligible for inclusion were patients with an Acute Physiology And Chronic Health Evaluation (APACHE) II score of at least 10 who were ready to be transferred to the surgical ward within 24 h of emergency abdominal surgery. Participants were randomized to either intermediate care or standard surgical ward care after surgery. The primary outcome was 30-day mortality. Results: In total, 286 patients were included in the modified intention-to-treat analysis. The trial was terminated after the interim analysis owing to slow recruitment and a lower than expected mortality rate. Eleven (7·6 per cent) of 144 patients assigned to intermediate care and 12 (8·5 per cent) of 142 patients assigned to ward care died within 30 days of surgery (odds ratio 0·91, 95 per cent c.i. 0·38 to 2·16; P = 0·828). Thirty (20·8 per cent) of 144 patients assigned to intermediate care and 37 (26·1 per cent) of 142 assigned to ward care died within the total observation period (hazard ratio 0·78, 95 per cent c.i. 0·48 to 1·26; P = 0·310). Conclusion: Postoperative intermediate care had no statistically significant effect on 30-day mortality after emergency abdominal surgery, nor any effect on secondary outcomes. The trial was stopped prematurely owing to slow recruitment and a much lower than expected mortality rate among the enrolled patients. Registration number: NCT01209663 (http://www.clinicaltrials.gov).

27 March 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HJHenrik Jakobsen
Henrik Jakobsen
MBMartin Saxtorph Bojer
Martin Saxtorph Bojer
MMMartin G. Marinus
Martin G. Marinus
TXTao Xu
Tao Xu
CSCarsten Struve
Carsten Struve
Anders Lobner-OlesenAnders Lobner-Olesen
Anders Lobner-Olesen
The nematode Caenorhabditis elegans has in recent years been proven to be a powerful in vivo model for testing antimicrobial compounds. We report here that the alkaloid compound Harmane (2-methyl-β-carboline) increases the lifespan of nematodes infected with a human pathogen, the Shiga toxin-producing Escherichia coli O157:H7 strain EDL933 and several other bacterial pathogens. This was shown to be unrelated to the weak antibiotic effect of Harmane. Using GFP-expressing E. coli EDL933, we showed that Harmane does not lower the colonization burden in the nematodes. We also found that the expression of the putative immune effector gene F35E12.5 was up-regulated in response to Harmane treatment. This indicates that Harmane stimulates the innate immune response of the nematode; thereby increasing its lifespan during bacterial infection. Expression of F35E12.5 is predominantly regulated through the p38 MAPK pathway; however, intriguingly the lifespan extension resulting from Harmane was higher in p38 MAPK-deficient nematodes. This indicates that Harmane has a complex effect on the innate immune system of C. elegans. Harmane could therefore be a useful tool in the further research into C. elegans immunity. Since the innate immunity of C. elegans has a high degree of evolutionary conservation, drugs such as Harmane could also be possible alternatives to classic antibiotics. The C. elegans model could prove to be useful for selection and development of such drugs.

28 September 2022 in Langenbeck's Archives of Surgery
Verified
Journal Article
Closed access
PDF file
NDNiclas Dohrn
Niclas Dohrn
COCarolin Oppermann
Carolin Oppermann
HYHelin Yikilmaz
Helin Yikilmaz
MLMagnus Laursen
Magnus Laursen
FKFaisal Khesrawi
Faisal Khesrawi
Ismail GögenurIsmail Gögenur
Ismail Gögenur

12 December 2025 in Science Immunology
Verified
Journal Article
Open access
TFThomas M. Fenton
Thomas M. Fenton
LWLine Wulff
Line Wulff
VVVenla Väänänen
Venla Väänänen
GJGareth-Rhys Jones
Gareth-Rhys Jones
CLCamilla Koldbæk Lemvigh
Camilla Koldbæk Lemvigh
WAWilliam W. Agace
William W. Agace
Understanding of mononuclear phagocyte (MNP) diversity in the human intestine and the alterations this compartment undergoes in inflammation remains incomplete. Here, we used single-cell RNA sequencing, cellular indexing of trancriptomes and epitopes by sequencing, flow cytometry, and imaging to explore MNP heterogeneity in human ileal and colonic laminae propriae (LPs) in health and Crohn’s disease (CD). In addition to monocytes, macrophage subsets, and conventional type 1 dendritic cells (cDC1s) and cDC2s, we found a CD1c + cDC subset with transcriptional features of DC3s. Using computational tools, we identified monocyte-to-macrophage trajectories as well as putative subset–specific DC precursors. We further showed that LP CCR7 + cDCs are increased in CD and provided evidence that these cells arise from intestinal cDC2s/DC3s but not cDC1s. Collectively, these findings extend our current understanding of intestinal MNP diversity and development, highlighting both tissue-specific and inflammation-induced changes in MNP composition and function.

1 June 2021 in European Urology
Verified
Journal Article
Closed access
LBL. Boesen
L. Boesen
VLV. Loegager
V. Loegager
NNN. Nørgaard
N. Nørgaard
KNK.J. Nielsen
K.J. Nielsen
RBR. Bisbjerg
R. Bisbjerg
HTH.S. Thomsen
H.S. Thomsen